GLP -1 -Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist researched for its ability to improve glycemic control and support weight management. By mimicking natural GLP-1 activity, it stimulates insulin secretion, reduces glucagon release, slows gastric emptying, and promotes satiety. Clinical studies suggest it may lead to significant weight loss, improved glucose tolerance, and reduced cardiovascular risk factors.